ENDRA Life Sciences Inc (NDRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ENDRA Life Sciences Inc (NDRA) has a cash flow conversion efficiency ratio of -0.627x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.12 Million) by net assets ($1.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of ENDRA Life Sciences Inc to measure how much of total assets are equity-financed.
ENDRA Life Sciences Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how ENDRA Life Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow reinvestment rate of ENDRA Life Sciences Inc to assess the company's total reinvestment commitment from operating cash flow.
ENDRA Life Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ENDRA Life Sciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LCL Resources Ltd
AU:LCL
|
-0.033x |
|
Plascar Participações Industriais S.A
SA:PLAS3
|
-0.007x |
|
Permsin Steel Works Public Company Limited
BK:PERM
|
0.167x |
|
SKAKO A/S
CO:SKAKO
|
0.066x |
|
Castelbajac Co. Ltd
KQ:308100
|
0.011x |
|
artec technologies AG
F:A6T
|
-0.014x |
|
Trinex Minerals Ltd
AU:TX3
|
-0.213x |
|
Iron Road Ltd
AU:IRD
|
-0.021x |
Annual Cash Flow Conversion Efficiency for ENDRA Life Sciences Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of ENDRA Life Sciences Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of ENDRA Life Sciences Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.26 Million | $-5.18 Million | -2.293x | +20.67% |
| 2024-12-31 | $2.56 Million | $-7.40 Million | -2.890x | -71.30% |
| 2023-12-31 | $5.66 Million | $-9.55 Million | -1.687x | +4.80% |
| 2022-12-31 | $7.20 Million | $-12.77 Million | -1.772x | -71.85% |
| 2021-12-31 | $10.78 Million | $-11.12 Million | -1.031x | +31.35% |
| 2020-12-31 | $7.17 Million | $-10.77 Million | -1.502x | +16.73% |
| 2019-12-31 | $4.76 Million | $-8.59 Million | -1.804x | -46.35% |
| 2018-12-31 | $6.25 Million | $-7.70 Million | -1.233x | -97.02% |
| 2017-12-31 | $5.28 Million | $-3.30 Million | -0.626x | -142.51% |
| 2016-12-31 | $-893.77K | $-1.32 Million | 1.472x | +143.72% |
| 2015-12-31 | $250.30K | $-842.73K | -3.367x | -45.87% |
| 2014-12-31 | $605.33K | $-1.40 Million | -2.308x | -- |
About ENDRA Life Sciences Inc
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fa… Read more